Antisense technology is now beginning to deliver on its promise to treat diseases by
targeting RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs representing …

Background: Contemporary studies suggest that familial hypercholesterolemia (FH) is more
frequent than previously reported and increasingly recognized as affecting individuals of all …

Every 5 years, the JAS publishes guidelines for the treatment of dyslipidemia and
atherosclerosis. To date, this society has released four such guidelines. Since 2007, the JAS …

Material de distribuição exclusiva à classe médica. Os Arquivos Brasileiros de Cardiologia
não se responsabilizam pelo acesso indevido a seu conteúdo e que contrarie a …

Familial hypercholesterolaemia (FH) is a common genetic cause of premature coronary
heart disease (CHD). Globally, one baby is born with FH every minute. If diagnosed and …

2168 Circulation December 1, 2015 sufficient evidence for health benefit exists to implement
case finding via family history–based screening, cascade screening, or other strategies …

Abstract Aims Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening
condition characterized by markedly elevated circulating levels of low-density lipoprotein …

Background Homozygous familial hypercholesterolaemia is a rare, serious disorder caused
by very low or absent plasma clearance of LDL, substantially raised LDL cholesterol, and …

Familial hypercholesterolaemia is common in individuals who had a myocardial infarction at
a young age. As many as one in 200 people could have heterozygous familial …

Background Patients with homozygous familial hypercholesterolaemia respond
inadequately to existing drugs. We aimed to assess the efficacy and safety of the microsomal …